Biogen lowers 2026 earnings guidance and projects mid-single-digit revenue decline
Updated
Updated · The Wall Street Journal · Apr 29
Biogen lowers 2026 earnings guidance and projects mid-single-digit revenue decline
11 articles · Updated · The Wall Street Journal · Apr 29
Biogen now expects 2026 earnings of $14.25–$15.25 per share and revenue to fall from $9.89 billion in 2025.
The company attributes the outlook to acquired R&D charges and anticipated lower multiple sclerosis product revenue, despite first-quarter net income rising to $319.5 million and revenue beating forecasts.
Biogen's guidance excludes the impact of its Apellis acquisition, which is expected to boost adjusted earnings growth from 2027 onward.
Despite a strong Q1, why is Biogen signaling a tougher financial road ahead for 2026?
Is Biogen's spending spree a bet on new drugs or on an AI-powered discovery revolution?
Analysts are divided on Biogen. Is it a smart turnaround investment or a falling giant?
Is Biogen's Alzheimer's drug growing fast enough to win the high-stakes race against its rivals?
Can two newly acquired drugs truly replace Biogen's declining multi-billion dollar MS franchise?